Skip to main content

About

Aims and scope

Clinical Proteomics encompasses all aspects of translational proteomics. This includes quantitative and qualitative profiling of proteins and peptides that are present in clinical specimens like human tissues and body fluids. Special emphasis is placed on the application of proteomic technology to all aspects of clinical research and molecular medicine.
 
As an open access journal, Clinical Proteomics is committed to rapid scientific review and timely publication of submitted manuscripts. This is achieved by receiving, processing and publishing submissions online. As molecular medicine moves beyond genomics to proteomics, the goal becomes the characterization of the cellular circuitry and the understanding of the impact of disease and therapy on precision medicine.
 
Clinical Proteomics provides a scholarly forum for novel scientific research in the field of translational proteomics. The journal is publishing manuscripts with significant scientific discoveries or observations related to human diseases, for example the discovery and analytical and preclinical validation of novel diagnostic or therapy related markers, the potential of protein profiles for the development of personalized medicine. This will include original research articles and reviews in proteomics and bioinformatics. Articles in the development and application of technologies, clinical studies, methodologies, and protocols are also welcome.

Open access

All articles published by Clinical Proteomics are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Clinical Proteomics you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article processing charges (APC)

Authors who publish open access in Clinical Proteomics are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £1790.00/$2490.00/€2090.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Indexing services

All articles published in Clinical Proteomics are included in:

  • Cinahl
  • Citebase
  • DOAJ
  • Embase
  • Index to Chiropractic Literature
  • OAIster
  • PubMed
  • PubMed Central
  • Scopus
  • SOCOLAR
  • ​Zetoc

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.

 Clinical Proteomics has an Impact Factor of 3.476.

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.



Clinical Proteomics operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Manuscripts will be assigned to a handling Editor, who will appoint at least two referees. On receipt of their reports the handling Editor will make a recommendation to accept, to accept with minor revisions, to request major revisions and resubmission, or to reject. No manuscript will be rejected without being assessed by a member of the Editorial Board and one other expert.

Clinical Proteomics considers the following types of article: Letter to the Editor, Meeting report, Research, and Review. For more specific information, please take a look at our Submission Guidelines.

Editorial policies

All manuscripts submitted to Clinical Proteomics should adhere to BioMed Central's editorial policies.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Citing articles in Clinical Proteomics

Articles in Clinical Proteomics  should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Clin Proteomics [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Proteomics 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.

Benefits of publishing with BMC

High visibility

Clinical Proteomics's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Clinical Proteomics offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Clinical Proteomics gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Clinical Proteomics are included in article alerts and regular email updates. Some may be highlighted on Clinical Proteomics’s pages and on the BMC homepage.

In addition, articles published in Clinical Proteomics may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical Proteomics. A list of articles recently press-released by journals published by BMC is available here.

Copyright

As an author of an article published in Clinical Proteomics you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).

For further information about the advantages of publishing in a journal from BMC, please click here.

Annual Journal Metrics

  • 2022 Citation Impact
    3.8 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    0.873 - SNIP (Source Normalized Impact per Paper)
    0.941 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    159 days submission to accept (Median)

    2023 Usage
    434,196 downloads
    385 Altmetric mentions